Background: Bariatric surgery in Canada is primarily delivered within publicly funded specialty clinics. Previous studies have demonstrated that bariatric surgery is superior to intensive medical management for reduction of weight and obesity-related comorbidities. Our objective was to compare the effectiveness and safety of laparoscopic Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (LSG) and adjustable gastric banding (LAGB) in a publicly funded, population-based bariatric treatment program.
T he prevalence of obesity in Canada has increased 225% since 1985. 1 In absolute terms, approximately 60% of Canadians are overweight and 24% are defined as clinically obese (body mass index [BMI] > 30). 2 The majority of this increased prevalence is accounted for by increases in class II (BMI > 35) and class III (BMI > 40) obesity.
1 Individuals with obesity demonstrate a 2-to 5-fold greater prevalence of type 2 diabetes, a 2-to 4-fold increased prevalence of cardiovascular risk factors (coronary artery disease, hypertension), and a reduction in life expectancy by 8 to 13 years 3,4 compared with individuals with a healthy weight. Substantial increases in obesityrelated morbidity and associated health care expenditures have been recognized. [5] [6] [7] The weight loss effectiveness of bariatric surgery compared with medical management of obesity is well documented. [8] [9] [10] In a recent randomized controlled study in a private U.S. health care setting, Schauer and colleagues 11 demonstrated increased weight loss and improvement in type 2 diabetes 36 months following bariatric surgery compared with intensive medical management. Similarly, a recent meta-analysis by Padwal and colleagues 12 reported substantial weight loss following bariatric surgery with low overall complication rates.
Parallel to the growing evidence supporting surgery over medical management, the number of people undergoing bariatric surgery has doubled worldwide (up to 350 000 procedures/yr) since 2000. 13 Accordingly, funding for bariatric surgical care in Canada has greatly increased. For instance, in 2009 the province of Ontario contributed $75 million in public funding toward a Bariatric Care Network, and the province of Quebec has doubled the number of bariatric procedures from 1000 to 2000 per year since 2005. 14, 15 Bariatric surgical care in Canada is largely delivered within specialized multidisciplinary programs with central referral and triage. 15, 16 Compared with bariatric centres in the United States that are generally privately funded, the typical patient encountered in a public setting is likely to be of lower socioeconomic status, less highly selected and possibly more treatment-refractory. Therefore, outcomes in Canadian patients may differ from those of patients enrolled in studies from other countries. 3, 17, 18 In Alberta, the Edmonton Adult Bariatric Specialty program is a publicly funded venture offering a tiered approach for centrally referred patients, who progress from a wait list to intensive medical management and ultimately to bariatric surgery (if indicated). In this clinic, there is no systematic process for choosing a specific type of bariatric surgery. Instead, a combination of empirical evidence, patient preference, institutional practice and surgeon advice is used.
At present, there is a lack of longitudinal studies that compare the effectiveness and safety of the common bariatric procedures on patients with obesity enrolled in a population-based, publicly funded system. Consequently, the objective of this prospective cohort analysis was to compare weight loss, safety and obesity-related outcomes of laparoscopic Roux-en-Y gastric bypass (RYGB), laparoscopic sleeve gastrectomy (LSG) and laparoscopic adjustable gastric banding (LAGB).
Methods
A detailed study protocol, approved by the University of Alberta Health Research Ethics Board, has been previously published. 3 All participants provided written informed consent.
Setting
The Edmonton Adult Bariatric Specialty program serves nearly 1.6 million residents within the Edmonton zone of the Alberta Health Services (AHS) network and constitutes one of the largest health care delivery systems in Canada. The program itself is a centralized, single point of access referral system for patients with a BMI or 40 or higher, or with a BMI of 35 or higher as well as obesityrelated comorbidities (e.g., type 2 diabetes, sleep apnea, hypertension, osteoarthritis). All patients are placed on a wait list (first come first serve), and upon enrolment patients undergo intensive multidisciplinary evaluation and care, including health behaviour management, psycho logical support for mental illness and prior abuse and, if indicated, bariatric surgery. 6 Between November 2008 and November 2011, this program received 2598 new patient referrals who were wait listed for enrolment (average wait time of 2 yr); of those who continued in the program, 2116 were enrolled in medical management and 498 bariatric surgeries were performed. All procedures were performed by 1 of 3 bariatric surgeons at a large tertiary teaching hospital in Edmonton, Alta. The surgical procedures are described in Appendix 1, available at canjsurg.ca.
Participants and study groups
Between November 2008 and November 2011, consecutive, consenting surgical patients aged 18-60 years from the Adult Bariatric Specialty program were enrolled into the Alberta Population-based Prospective Evaluation of the Quality of Life Outcomes and Economic Impact of Bariatric Surgery (APPLES) study. The overall results of this cohort, including 2-year weight changes in waitlisted, medically treated and surgically treated patients has been previously detailed. 3 The present study focuses on detailing the results and adverse effects of surgical subgroups. Inclusion criteria and BMI thresholds for surgery were the same as the inclusion criteria for the APPLES study. Absolute contraindications to surgery included pregnancy or nursing, uncontrolled psychiatric illness, active smoking or substance abuse, active eating disorders, or a high-risk medicosurgical comorbidity (e.g., severe coronary artery disease) precluding an operation. All surgical patients underwent approximately 24-36 weeks of intensive, multidisciplinary management of obesity, obesity-related comorbidities and mental health screening before the decision to undergo surgery was made. Approval for surgery was a joint decision between the patient and a multidisciplinary team, taking into account the perceived likelihood of adherence to postoperative instructions and diet. Patients accepted for surgery continued on close medical monitoring while waiting for the procedure to be performed (10-14 mo).
For approved patients, the choice of RYGB versus LSG versus LAGB was made based on surgeon advice, patient preference and local patterns of practice.
Measurements and data collection
Detailed case report forms have been previously published. 6 Baseline data were collected within 2 weeks before surgery and included age, sex, race, marital status, employment status, household income, general medical history and obesity-related comorbidities, smoking status (current, past, never), medications, weight, BMI, waist circumference, blood pressure, fasting lipid levels, fasting glucose level, hemoglobin A1c (HbA1c) insulin and C-reactive protein (CRP). Body weight was recorded to the nearest 0.1 kg using a validated, calibrated bariatric scale (Scale Tronix, serial numbers 6702-4440 and 6702-6229). Participants wore light indoor clothing with empty pockets, no shoes and had an empty bladder. Height was measured to the nearest 0.1 cm using a wallmounted stadiometer. A single reading taken using an automated blood pressure monitor and appropriately sized blood pressure cuff was recorded after 5 min of seated rest.
Outcomes
The primary study outcome was weight change (in kilograms), measured every 6 months over the 2-year period. Both absolute and relative changes from baseline were analyzed. Ten percent weight reduction thresholds were also examined. 19 Secondary outcomes included hypertension, dyslipidemia and glycemic control. Hypertension was considered present if self-reported, if blood pressure levels were 140/90 mm Hg or more (≥ 130 mm Hg in patients with type 2 diabetes), or if patients were currently taking antihypertensive medications. Type 2 diabetes was considered present if self-reported, if HbA 1 c was 6.5% or greater, if fasting glucose level was 7.0 mmol/L or greater, or if patients were currently taking antidiabetic medications. Insulin resistance was assessed using the homeostatic model (HOMA-IR), as previously reported. 20 Dyslipidemia was considered present if self-reported, if the patient was currently taking lipid lowering therapy or if any of the following biochemical parameters were present: total cholesterol of 6.2 mmol/L or greater, low-density lipoprotein (LDL) of 4.1 mmol/L or greater, high-density lipoprotein (HDL) less than 1.0 mmol/L, or triglycerides of 2.3 mmol/L or greater. Obesity-related comorbidities were considered present if any of the above-mentioned specific criteria were present. Comorbidity resolution was defined as the absence of all of the comorbidity-specific criteria listed above at any point during follow-up.
Adverse events
Adverse events were documented prospectively throughout follow-up appointments and classified according to a modified Clavien-Dindo surgical complications system, focusing on grades III or higher. 21, 22 Grade V complications were defined as death. Grade IV and grade III events included those requiring surgical, radiologic or endoscopic intervention. Major surgical adverse events, such as gastrointestinal/staple line leakage or bleeding, were confirmed intraoperatively. Anastomotic ulcers and strictures were confirmed endoscopically. Abscess or band slippage and hernia were confirmed with computed tomography if clinically suspected.
Statistical analysis
We performed descriptive analyses, including calculation of proportions, means, standard deviations, medians and interquartile ranges as appropriate. Within-group change scores were calculated and normality assumptions verified. Baseline variables were compared among study groups using 1-way analysis of variance (ANOVA) for continuous outcomes and χ 2 tests for dichotomous ones. Between-group change scores were compared using 2-way ANOVA plus Bonferroni post hoc or multivariable linear regression, adjusting for age, sex and baseline BMI with adjusted prediction and average marginal effects. 23 We considered results to be significant at p < 0.05. Patients were censored if they became pregnant (n = 2) or underwent a second (different) bariatric surgical procedure within the program (n = 1). We used a lastobservation-carried-forward (LOCF) analysis to account for censoring or missing data in the primary analysis. We then repeated this analysis using a more conservative baseline-observation-carried-forward (BOCF) analysis as well as a more liberal (completers) analysis, including only patients who reached the 2 years of follow-up. We did not perform multiple imputations because the data were not missing completely at random. All analyses were performed using SAS software version 9.3 and STATA software version 14.1.
Results

Participants
We enrolled 150 consecutive, consenting surgical patients in our study: 51 underwent RYGB, 51 underwent LSG and 48 underwent LAGB.
Baseline characteristics
Baseline characteristics of the study group are presented in Table 1 . The mean age was 43.5 ± 9.5 years, and 87.3% of patients were women. On average, patients were in the severe obesity category with a mean BMI of 46.2 ± 7.4. There were statistically significant differences in the baseline BMI among participants undergoing different bariatric procedures, with BMI being lower in the LAGB group and larger in the RYGB group (Table 1) . In terms of obesity-related comorbidities, there were no statistically significant differences among groups in blood pressure, lipid profile, HbA1c, fasting glucose, HOMA-IR index or plasma levels of CRP. Additionally, patients tended to come from varied socioeconomic backgrounds, including all levels of education, income ranges and family status. The percentage of patients who successfully completed the 2-year follow-up was 86.2% in the RYGB group, 84.6% in the LSG group and 87.5% in the LAGB group (Fig. 1) .
Overall weight changes
In the primary LOCF analysis, absolute and relative (% of baseline) mean weight losses were 36.6 ± 19.5 kg (26.1 ± 12.2%) in the RYGB group, 21.4 ± 16.0 kg (16.4 ± 11.6%) in the LSG group, and 7.0 ± 9.7 kg (5.8 ± 7.9%) in the LAGB group (p < 0.001, ANOVA). Results of the BOCF and completers analyses were consistent with the primary analysis ( Table 2 ). There was a significantly greater total weight loss and BMI reduction when comparing the RYGB group to the LSG and LAGB groups (both p < 0.05), as well as when comparing the LSG group to the RYGB group (all p < 0.05) at all time points ( Fig. 2A and B) . The proportion of 5% and 10% responders was significantly reduced in the RYGB group compared with other surgical groups at any time point (Fig. 2C and D) .
Obesity-related comorbidities
At 2 years, the prevalence of type 2 diabetes, hypertension and dyslipidemia was reduced in all 3 surgical groups. For type 2 diabetes, the reduction in absolute prevalence was 33.3% for RYGB, 21.6% for LSG and 12.5% for LAGB. For hypertension, the reduction in absolute prevalence was 31.4% for RYGB, 11.8% for LSG and 8.3% for LAGB. For dyslipidemia, the reduction in absolute prevalence was 45.1% for RYGB, 31.3% for LSG and 18.8% for LAGB. While the change in absolute prevalence of type 2 diabetes, hypertension and dyslipidemia did not reach statistical significance between LSG and RYGB or between LSG and LAGB, there was a significantly greater change in prevalence after RYGB compared with LAGB at 2 years. Absolute and relative change in prevalence of comorbidities are presented in Figure 3 . The 2-year changes in cardiovascular risk factors are shown in Table 3 .
Adverse events
Adverse events were classified according to a modified Clavien-Dindo surgical complications system, focusing on grade III or higher. 21, 22 All reported adverse events required intervention, admission, or reoperation (Table 4) . Total adverse event rates were 19.6% for RYGB, 9.8% for LSG and 14.6% for LAGB. There were no deaths in any group at 2-year follow-up. Surgical adverse events included 2 anastomotic/staple line leaks and 2 intraabdominal abscesses requiring radiologic drainage in the RYGB group. ∆ BMI -13.0 ± 6.7 -7.5 ± 5.8 -2.7 ± 3.6 < 0.001 There were 4 internal hernias after 1 year in the RYGB group, all of which required reoperation, and 3 anastomotic ulcers that were treated medically. There was 1 anastomotic/ staple line bleed in the LSG group that required urgent reoperation and 1 intra-abdominal abscess that required radiologic drainage. There were 6 reoperations for band removal in the LAGB group. Other serious adverse events included 1 non-ST elevation myocardial infarction and 1 cardiac arrhythmia that required chemical cardioversion and 1 pulmonary embolus that required anticoagulation in the LSG group. In total, there were 21 grade IIIa or IIIb complications, and 1 grade IV complication.
discussion
To our knowledge, this is the first study to compare the effectiveness and safety of 3 common bariatric surgical approaches in a population-based, publicly funded, centrally triaged bariatric program. In this cohort with class III (BMI > 40) obesity, RYGB and LSG were effective in producing clinically important weight loss over a 2-year follow-up period. The RYGB procedure tended to produce the largest reduction in weight loss, followed by LSG, with the LAGB demonstrating modest weight loss at best. Additionally, RYGB demonstrated superiority in reducing type 2 diabetes, hypertension and dyslipidemia as compared with LAGB. In terms of safety, there were no deaths in any group and low rates of major adverse effects. Both the RYGB and LSG groups had low rates of major early postoperative adverse effects, most importantly anastomotic/staple line leakage and gastrointestinal/staple line bleeding. The RYGB had the second highest rate of postoperative surgical intervention, with LAGB being the highest related to issues requiring removal of the band.
Comparison
Previous clinical trials have demonstrated the superiority of bariatric surgery combined with intensive medical treatment compared with medical treatment alone in obese individuals. 11 A randomized controlled trial by O'Brien and colleagues 24 reported significantly greater short-term and long-term (10-yr) weight reduction following LAGB compared with intensive medical weight loss in patients with a BMI of 30-35.
2, 24 Schauer and colleagues 11 compared intensive medical treatment and RYGB or LSG versus intensive medical treatment alone and also demonstrated greater weight loss and type 2 diabetes remission in both surgical groups with class II obesity (BMI > 35). Comparatively, both the trials by O'Brien and colleagues 24 and Schauer and colleagues 11 included patients with lower average BMIs than our populationbased cohort (BMI 30-37 v. BMI > 40).
Additionally, comparative trials for bariatric surgical procedures are sparse in the literature. A prospective trial comparing RYGB versus LAGB by Angrisani and colleagues 25 randomized 51 patients with a mean BMI of 43. 2, 25 At 5-year follow up, the RYGB group had significantly greater weight reduction than the LAGB group Absolute and relative change in prevalence of comorbidities 2 years after surgery. Data presented as (A) absolute and (B) relative reduction in the proportion of participants with diabetes, hypertension and dyslipidemia 2 years after bariatric surgery. *Represents a significant change in prevalence (p < 0.05) relative to baseline in the same surgical subgroup. †Represents a significant difference in the prevalence of each risk factor compared to the effect observed in the those receiving laparoscopic adjustable gastric banding (LAGB). LSG = laparoscopic sleeve gastrectomy; RYGB = laparoscopic Roux-en-Y gastric bypass. (BMI 29.8 v. 34.9). The patients undergoing LAGB in their study had a change in BMI from 43.4 to 34.9, which was relatively greater than the modest -2.6 change in BMI seen in our cohort at 2-year follow-up. Interestingly, Christou and colleagues 26 retrospectively reviewed outcomes of RYGB versus LAGB in Canada with 5-year outcomes. Similar to our findings, they also reported significantly greater weight loss with RYGB than with LAGB. Sjöström and colleagues 27 reported 15-year follow-up data comparing RYGB, LAGB and vertical-banded gastroplasty. Their study did not include LSG, as it is the newest of the 3 procedures. At 2-year follow-up, the weight loss was 32% for RYGB and 20% for LAGB compared with baseline. Interestingly, in our study weight loss after RYGB was comparable; however, weight loss after LAGB was considerably less. It remains difficult to define the factors responsible for the variability in weight loss seen with LAGB among studies. Differences may relate to variations in patient selection (inclusion and exclusion criteria), local patterns of practice, or study design. This variability is unlikely related to different gastric banding devices or techniques, as previous trials have demonstrated. 28, 29 Our data not only demonstrate marginal absolute weight loss with LAGB, but also superior comparative weight loss with LSG and RYGB, and greater reduction in obesity-related comorbidities with RYGB. Accordingly, in a shared decision-making model, our study will inform patients and referring physicians of the relative lack of effectiveness of the band for weight loss and comorbidity resolution. Also, our findings will inform bariatric surgeons that LAGB should not be routinely offered to patients with severe obesity who are interested in substantial weight loss and improvement in type 2 diabetes, hypertension and dyslipidemia. Instead, the primary bariatric surgical approach for these patients should consist of RYGB or LSG.
Our data also suggest that all 3 bariatric surgical procedures are safe. This is similar to the systematic review by Chang and colleagues 30 in which mortality was 0.08% in a population of 161 756 patients. Both RYGB and LSG had greater and more serious adverse event rates than LAGB, related to the anastomotic and staple line challenges. However, the complication rates were similar to those reported in previous studies.
11 ,25 We acknowledge that given the relative infrequency of these adverse effects, this study is likely underpowered to detect true differences in adverse effects.
Limitations
The APPLES surgical cohort analysis is unique in that it provides prospective data with a relatively large study population to compare 3 common types of bariatric surgery with relatively modest loss to follow-up. The major limitation is the nonrandomized nature of the study. This resulted in baseline imbalances in weight, which we addressed using regression techniques. In terms of generalizability, this study should be generalizable to publicly funded bariatric programs in Canada; however, generalizability beyond Canada should be made with caution. Additionally, with obesity being a chronic disease, our data provide only short-term follow up.
conclusion
The RYGB and LSG procedures were substantially more effective for weight loss and resolution of obesity-related comorbid disease than LAGB in our population-based cohort. Although RYGB and LSG were associated with greater perioperative risk, these adverse effects were uncommon, and the weight loss efficacy of LAGB was relatively poor. Our findings will inform patients, primary physicians, multidisciplinary teams and surgeons in Canada regarding the effectiveness and safety of the 3 most common bariatric surgical procedures. Furthermore, our findings support the preferential use of RYGB and LSG in publicly funded bariatric surgical programs in Canada. 
